Robert Edward Walker - 14 Apr 2026 Form 4 Insider Report for NOVAVAX INC (NVAX)

Reporting relationship: EVP, R&D
Issuer ticker: NVAX
Reported as of: 14 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Apr 2026, 18:13:00 UTC
Source filing: View source filing
Reporting owner signature: /s/ Mark J. Casey, Attorney-in-Fact

Key filing fact

Robert Edward Walker filed Form 4 for NOVAVAX INC (NVAX) on 16 Apr 2026.

Key facts

This page summarizes Robert Edward Walker's Form 4 filing for NOVAVAX INC (NVAX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Apr 2026, 18:13.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002127840 Primary reporting owner

Walker Robert Edward

Relationship: EVP, R&D
Address: C/O NOVAVAX, INC., 21 FIRSTFIELD ROAD, GAITHERSBURG
Signature: /s/ Mark J. Casey, Attorney-in-Fact
Signature date: 16 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVAX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +99,500
Change %
Price: $0.000000^*
Shares after: 99,500
Date: 14 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 99,500
Exercise price: $8.46
Footnotes: F1

NVAX transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +66,000
Change %
Price: $0.000000^*
Shares after: 6,600
Date: 14 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 66,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.

Footnote F2

Each RSU represents a contingent right to receive one share of the "Company" common stock.

Footnote F3

The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the April 14, 2026 grant date, in each case subject to continued employment with the Company through such vesting date.